JP7536424B2 - 多重特異性分子 - Google Patents

多重特異性分子 Download PDF

Info

Publication number
JP7536424B2
JP7536424B2 JP2018563747A JP2018563747A JP7536424B2 JP 7536424 B2 JP7536424 B2 JP 7536424B2 JP 2018563747 A JP2018563747 A JP 2018563747A JP 2018563747 A JP2018563747 A JP 2018563747A JP 7536424 B2 JP7536424 B2 JP 7536424B2
Authority
JP
Japan
Prior art keywords
binding
antibody
vld
bdm
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510812A5 (enExample
JP2019510812A (ja
Inventor
アンソニー・サイモン・ロバーツ
ジョージ・コプシダス
マイケル・ロス・ルーク
フィル・アンソニー・ジェニングス
Original Assignee
イミュネクサス・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900708A external-priority patent/AU2016900708A0/en
Application filed by イミュネクサス・セラピューティクス・リミテッド filed Critical イミュネクサス・セラピューティクス・リミテッド
Publication of JP2019510812A publication Critical patent/JP2019510812A/ja
Publication of JP2019510812A5 publication Critical patent/JP2019510812A5/ja
Priority to JP2022078237A priority Critical patent/JP2022105574A/ja
Priority to JP2023219531A priority patent/JP7857274B2/ja
Application granted granted Critical
Publication of JP7536424B2 publication Critical patent/JP7536424B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018563747A 2016-02-26 2017-02-27 多重特異性分子 Active JP7536424B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022078237A JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子
JP2023219531A JP7857274B2 (ja) 2016-02-26 2023-12-26 多重特異性分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900708A AU2016900708A0 (en) 2016-02-26 Multi-specific molecules 1
AU2016900709A AU2016900709A0 (en) 2016-02-26 Multi-specific molecules 2
AU2016900709 2016-02-26
AU2016900708 2016-02-26
PCT/AU2017/050168 WO2017143406A1 (en) 2016-02-26 2017-02-27 Multi-specific molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022078237A Division JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子

Publications (3)

Publication Number Publication Date
JP2019510812A JP2019510812A (ja) 2019-04-18
JP2019510812A5 JP2019510812A5 (enExample) 2020-04-09
JP7536424B2 true JP7536424B2 (ja) 2024-08-20

Family

ID=59685848

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563747A Active JP7536424B2 (ja) 2016-02-26 2017-02-27 多重特異性分子
JP2022078237A Pending JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子
JP2023219531A Active JP7857274B2 (ja) 2016-02-26 2023-12-26 多重特異性分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022078237A Pending JP2022105574A (ja) 2016-02-26 2022-05-11 多重特異性分子
JP2023219531A Active JP7857274B2 (ja) 2016-02-26 2023-12-26 多重特異性分子

Country Status (7)

Country Link
US (4) US20190338013A1 (enExample)
EP (1) EP3419667A4 (enExample)
JP (3) JP7536424B2 (enExample)
CN (1) CN109310766A (enExample)
AU (2) AU2017222700B2 (enExample)
TW (1) TW201734037A (enExample)
WO (1) WO2017143406A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017222700B2 (en) * 2016-02-26 2018-09-27 Imunexus Therapeutics Limited Multi-specific molecules
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
IL270743B2 (en) 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
KR20210029298A (ko) * 2017-08-16 2021-03-15 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
CN111836832A (zh) * 2018-01-08 2020-10-27 南京传奇生物科技有限公司 多特异性抗原结合蛋白及其使用方法
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
US20230002450A1 (en) * 2019-02-18 2023-01-05 Courier Therapeutics, Inc. Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
WO2021147857A1 (en) * 2020-01-20 2021-07-29 Wuxi Biologics (Shanghai) Co., Ltd A novel wash buffer solution for affinity chromatography
EP3904378A1 (en) * 2020-04-29 2021-11-03 Hober Biotech AB Bispecific protein
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US11993657B2 (en) * 2021-03-16 2024-05-28 Jn Biosciences Llc Bifunctional molecules for treatment of immune disorders
JP2024543164A (ja) * 2021-11-26 2024-11-19 イミュネクサス・セラピューティクス・リミテッド 細胞表面上の結合ドメイン分子
CN115078718B (zh) * 2022-07-22 2024-11-12 福建师范大学 一种基于表面增强拉曼技术检测透明质酸酶的方法
KR20250087648A (ko) * 2022-11-09 2025-06-16 리플리겐 코포레이션 친화도 제제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505103A (ja) 1998-03-06 2002-02-19 ダイアテック・ピーティワイ・リミテッド Ｖ様ドメイン結合分子
JP2010518062A (ja) 2007-02-08 2010-05-27 ドマンティス リミテッド 血清アルブミンに対する抗体単一可変ドメイン
JP2011504742A (ja) 2007-11-30 2011-02-17 グラクソ グループ リミテッド 抗原結合性構築物
JP2012528112A (ja) 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合タンパク質

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060070A1 (en) * 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
WO2010136485A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
AU2017222700B2 (en) * 2016-02-26 2018-09-27 Imunexus Therapeutics Limited Multi-specific molecules
JP2024543164A (ja) * 2021-11-26 2024-11-19 イミュネクサス・セラピューティクス・リミテッド 細胞表面上の結合ドメイン分子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505103A (ja) 1998-03-06 2002-02-19 ダイアテック・ピーティワイ・リミテッド Ｖ様ドメイン結合分子
JP2010518062A (ja) 2007-02-08 2010-05-27 ドマンティス リミテッド 血清アルブミンに対する抗体単一可変ドメイン
JP2011504742A (ja) 2007-11-30 2011-02-17 グラクソ グループ リミテッド 抗原結合性構築物
JP2012528112A (ja) 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合タンパク質

Also Published As

Publication number Publication date
AU2019200005A1 (en) 2019-01-24
AU2017222700B2 (en) 2018-09-27
US20210230249A1 (en) 2021-07-29
EP3419667A1 (en) 2019-01-02
JP2024026531A (ja) 2024-02-28
JP7857274B2 (ja) 2026-05-12
JP2022105574A (ja) 2022-07-14
US20190338013A1 (en) 2019-11-07
CN109310766A (zh) 2019-02-05
TW201734037A (zh) 2017-10-01
WO2017143406A1 (en) 2017-08-31
US20240182542A1 (en) 2024-06-06
US20210040177A1 (en) 2021-02-11
JP2019510812A (ja) 2019-04-18
EP3419667A4 (en) 2019-10-23
US11345736B2 (en) 2022-05-31
AU2017222700A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
US11345736B2 (en) Multi-specific molecules
US12324837B2 (en) ROR1-specific antigen binding molecules
US11414497B2 (en) Anti-PSMA antibodies and use thereof
US20230293687A1 (en) T cells and chimeric stimulating receptors and uses thereof
US8043621B2 (en) Recombinant fusion protein and polynucleotide construct for immunotoxin production
US20230167200A1 (en) Platform for constructing multispecific antibody
US12600782B2 (en) Anti-PD-L1 and PD-L2 antibody and derivatives and use thereof
JP2024509910A (ja) Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質
CN117964767B (zh) 抗rage抗体、细胞外囊泡及其制备方法和应用
JP7490559B2 (ja) 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質
CN119137148A (zh) 结合白蛋白的多肽及其用途
WO2025148933A1 (zh) 抗体及其药物偶联物和用途
US12606628B2 (en) Antibodies targeting integrin beta-2
CN119060184A (zh) 抗rage抗体及其应用
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
KR20250085636A (ko) 신규 항-myct1 인간항체 및 이의 용도
EP4737482A1 (en) Humanized anti-myct1 antibody and use thereof
CN118440197A (zh) Pd-l1鲨鱼纳米抗体的制备及其对肿瘤的影响

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210405

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220511

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220518

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220708

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240807

R150 Certificate of patent or registration of utility model

Ref document number: 7536424

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150